FibroBiologics (FBLG) news
Recent news
FibroBioLogics appoints Leigh Steinberg to board of directors
AInvest Wire · 7d agoFibroBioLogics, Inc.: H.C. Wainwright cuts target price to $6 from $8
On August 4, 2026, H.C. Wainwright adjusted its price target for FibroBiologics, Inc. (FBLG), reducing it to $6 from a previous target of $8. This revision reflects a reassessment of the company’s stock potential amid recent market performance and analyst expectations. Over the past year, FBLG’s…
AInvest Wire · Aug 4, 2026FibroBioLogics - interim results for CYWC628 trial expected in second half of 2026
FibroBiologics Inc. has announced that interim results for its Phase 1/2 clinical trial of CYWC628, a cell therapy candidate for the treatment of diabetic foot ulcers, are expected in the second half of 2026. The company has completed third batch of CYWC628 drug product for the trial, marking…
AInvest Wire · Jul 31, 2026FibroBioLogics reports second quarter 2026 financial results; progresses clinical trial evaluating lead wound care candidate
FibroBiologics, Inc. (Nasdaq: FBLG) reported its second quarter 2026 financial results and provided an update on its clinical development activities. The company continues to advance its lead wound care candidate, CYWC628, in a Phase 1/2 clinical trial for the treatment of diabetic foot ulcers…
AInvest Wire · Jul 31, 2026FibroBioLogics - registers resale of up to 12.53 mln shares of common stock by selling stockholders - SEC filing
AInvest Wire · Jul 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.